Rachel A. Hodge
Oncology R&D, AstraZeneca
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic.
Journal: The Journal of molecular diagnostics : JMD
Published: December 21, 2022
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 12, 2022
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Journal: JCO precision oncology
Published: August 11, 2022
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.
Journal: Future oncology (London, England)
Published: November 01, 2021
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: September 21, 2020
Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.
Journal: Clinical lung cancer
Published: September 02, 2020
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
Journal: The New England journal of medicine
Published: November 22, 2019
The application of a haemorrhage assessment tool in evaluating control of bleeding in a pilot trauma haemorrhage trial.
Journal: Transfusion medicine (Oxford, England)
Published: May 01, 2019
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.
Journal: Japanese journal of clinical oncology
Published: October 05, 2018
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 29, 2018
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 31, 2018
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 03, 2018
Last Updated: 09/26/2026